Join
Live feed
·
PRReleasevia Quantisnow
Mirum Pharmaceuticals Inc. logo

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

ByQuantisnow·Wall Street's wire, on your screen.
MIRM· Mirum Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRM (Mirum Pharmaceuticals Inc.) and more on Quantisnow.